A5070158409- Breast Cancer Treatment Studies
- BRCA gene mutations in cancer
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Breast Lesions and Carcinomas
- PARP inhibition in cancer therapy
- Cancer Risks and Factors
- Estrogen and related hormone effects
- DNA Repair Mechanisms
- Multiple and Secondary Primary Cancers
- Ovarian cancer diagnosis and treatment
- Reproductive Biology and Fertility
- Global Cancer Incidence and Screening
- Endoplasmic Reticulum Stress and Disease
- Lung Cancer Treatments and Mutations
- Brain Metastases and Treatment
- Metabolism, Diabetes, and Cancer
- Immunotherapy and Immune Responses
- Neutropenia and Cancer Infections
- Cancer Immunotherapy and Biomarkers
- Ovarian function and disorders
- Cancer-related Molecular Pathways
- Genetic factors in colorectal cancer
Rabin Medical Center
2016-2025
Tel Aviv University
2016-2025
John Wiley & Sons (United States)
2021
Hudson Institute
2021
Centre National de la Recherche Scientifique
2019
Concord Repatriation General Hospital
2019
Aix-Marseille Université
2019
Inserm
2019
Mater Health Services
2017-2019
Seoul National University Hospital
2017-2019
Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which metastatic sites will be affected.Patients with cancer diagnosed between 1986 1992 archival tissue were included. Subtypes defined as luminal A, B, luminal/human epidermal growth factor receptor 2 (HER2), HER2 enriched, basal-like, triple negative (TN) nonbasal. Distant classified brain, liver, lung, bone, distant nodal, pleural/peritoneal, other. Cumulative incidence curves...
The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations BRCA1 BRCA2 ( BRCA1/2).We conducted a randomized, open-label, phase 3 trial which BRCA1/2 mutation were assigned, 2:1 ratio, to receive (1 mg once daily) or standard single-agent therapy of the physician's choice (capecitabine, eribulin, gemcitabine, vinorelbine continuous 21-day cycles). primary end point was progression-free survival,...
In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P < 0.0001) and improved patient-reported outcomes (PRO) in germline BRCA1/2 (gBRCA1/2)-mutated advanced breast cancer (ABC). We report final overall (OS).This randomized phase III trial enrolled patients with gBRCA1/2-mutated HER2-negative ABC. Patients received or physician's choice of chemotherapy. OS was analyzed using stratified HR log-rank...
Recent data suggest that human epidermal growth factor receptor 2 (HER2)-low breast cancer may represent a distinct entity. We aimed to compare disease characteristics and outcomes between HER2-low HER2-0 in estrogen (ER) positive, early-stage cancer.A single center retrospective study comprising all women with ER HER2 negative early cancer, for whom an Oncotype DX test was performed 2005 2012. Women were grouped (immunohistochemistry +1 or +2 situ hybridization not amplified) HER2-0....
In the EMBRACA phase III trial, talazoparib (1 mg daily, orally) demonstrated a statistically significant improvement in PFS versus physician's choice of chemotherapy (PCT; capecitabine, eribulin, gemcitabine, or vinorelbine) patients with HER2-negative advanced breast cancer carrying germline BRCA1/2 mutation; we evaluated patient-reported outcomes (PROs).Patients were randomized 2 : 1 to receive PCT. PROs assessed at day (baseline), start each treatment cycle (every 3 weeks), and end...
Importance Young women with breast cancer who have germline pathogenic variants in BRCA1 or BRCA2 face unique challenges regarding fertility. Previous studies demonstrating the feasibility and safety of pregnancy survivors included limited data BRCA carriers. Objective To investigate cumulative incidence disease-free survival young are Design, Setting, Participants International, multicenter, hospital-based, retrospective cohort study conducted at 78 participating centers worldwide. The...
Acquired estrogen receptor alpha (ER/ESR1) mutations commonly cause endocrine resistance in ER+ metastatic breast cancer (mBC). Lasofoxifene, a novel selective ER modulator, stabilizes an antagonist conformation of wild-type and ESR1-mutated ER-ligand binding domains, has antitumor activity xenografts.In this open-label, randomized, phase II, multicenter, ELAINE 1 study (NCT03781063), we randomized women with ESR1-mutated, ER+/human epidermal growth factor 2 negative (HER2-) mBC that had...
Abstract In DESTINY-Breast01 (NCT03248492) and DESTINY-Breast03 (NCT03529110), trastuzumab deruxtecan (T-DXd) demonstrated unprecedented activity in patients (pts) with HER2+ (immunohistochemistry 3+; immunohistochemistry 2+/in situ hybridization+) advanced metastatic breast cancer (mBC), leading to regulatory approvals several countries for unresectable/mBC after a prior anti–HER2-based regimen. DESTINY-Breast02 (NCT03523585) is phase 3 trial of T-DXd vs treatment physician’s choice (TPC)...
Chemotherapy-related amenorrhea is a frequent side effect observed in young breast cancer patients. Studies mice revealed that chemotherapy-induced gonadal toxicity may result from vascular damage. We prospectively evaluated ovarian blood flow and function patients following chemotherapy.Young female with localized undergoing adjuvant or neoadjuvant anthracycline- taxane-based chemotherapy were using transvaginal ultrasound prior to initiation of immediately after cessation chemotherapy....
Abstract Background: Talazoparib (TALA) is a highly potent, dual-mechanism PARP inhibitor that inhibits the enzyme and effectively traps on single-stranded DNA breaks, preventing damage repair causing cell death in BRCA1/2-mutated cells. Methods: EMBRACA an open-label, randomized, 2-arm, phase 3 trial comparing efficacy safety of TALA (1 mg/day) with standard single-agent physician's choice therapy (PCT) (capecitabine, eribulin, gemcitabine, or vinorelbine) patients advanced breast cancer...
Abstract Metastasis remains the leading cause (90%) of cancer-related mortality, especially in metastatic triple-negative breast cancer (TNBC). Improved understanding molecular drivers cascade is crucial, to find accurate prognostic markers for invasiveness after chemotherapy treatment. Current treatments include doxorubicin and paclitaxel, inducing various effects, such as unfolded protein response (UPR). The key regulator UPR 78-kDa glucose-regulated (GRP78), which associated with disease,...
Imatinib mesylate (IM) is a tyrosine kinase inhibitor, which inhibits phosphorylation of downstream proteins involved in BCR-ABL signal transduction. It has proved beneficial treating patients with chronic myeloid leukaemia (CML). In addition, IM demonstrates activity against malignant cells expressing c-kit and platelet-derived growth factor receptor (PDGF-R). The the blastic crisis CML various myeloma cell lines suggests that this drug may also target other cellular components. light...
Abstract Background. We previously reported that chemotherapy-induced ovarian toxicity may result from acute vascular insult, demonstrated by decreased blood flow and diminished post-treatment anti-Müllerian hormone (AMH) levels. In the present study, we report continuous prospective evaluation of function in cohort. Methods. Patients (aged &lt;43 years) with localized breast cancer were evaluated transvaginal ultrasound prior to initiation chemotherapy, immediately at treatment...